EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 10, 2011

Primary Completion Date

May 29, 2012

Study Completion Date

October 31, 2033

Conditions
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

autologous CAR.CD30 EBV specific-CTLs

Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER